Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.
For information only — not medical advice. Always talk to your nephrologist.
17 FDA-approved therapies since 2018 — 8 in the last two years — plus 3 trials enrolling now.
New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.
First-line care is blood-pressure control with an ACE inhibitor or ARB, good hydration, and lowering salt; tolvaptan is added for rapidly progressing disease. Your nephrologist typically starts here.
These are newer and recently approved therapies for Polycystic kidney disease — not the full standard of care. Ask your care team whether any fit your situation.
Vasopressin V2 receptor antagonist
Evidence: Slowed kidney growth (2.8% vs 5.5% per year) and reduced the rate of eGFR decline.
Source: FDA prescribing information; TEMPO 3:4, NEJM 2012Verified 2026-07-18
Actively enrolling studies related to Polycystic kidney disease. Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.
No actively enrolling trials we're tracking for Polycystic kidney disease right now.
For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.
Jump straight to treatments and enrolling trials for a specific kidney diagnosis.
Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.
Get started free